The economic returns of pediatric clinical trials of antihypertensive drugs

American Heart Journal

Volumn 156, Issue 4, 2008, Pages 682-688

  Baker Smith, Carissa M ^a   Benjamin Jr , Daniel K ^a,b   Grabowski, Henry G ^c   Reid, Elizabeth D ^b   Mangum, Barry ^b   Goldsmith, John V ^d   Murphy, M Dianne ^d   Edwards, Rex ^b   Eisenstein, Eric L ^b   Sun, Jessica ^a   Califf, Robert M ^b   Li, Jennifer S ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BIOEQUIVALENCE; CHILD; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; PEDIATRICS; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 53149083426     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.05.001     Document Type: Article

References (21)

1. Department of Health and Human Services, and U.S. Food and Drug Administration. The Pediatric Exclusivity Provision: January 2001 Status Report to Congress. Available at:. http://www.fda.gov/cder/pediatric/reportcong01.pdf. Last accessed November 27, 2007
2. Department of Health and Human Services, and U.S. Food and Drug Administration. Approved active moieties to which FDA has issued a written request for pediatric studies under Section 505A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration Web site. Available at:. http://www.fda.gov/cder/Pediatric/wrlist.htm. Last accessed November 27, 2007
3. Department of Health and Human Services, and U.S. Food and Drug Administration. Pediatric exclusivity labeling changes. US Food and Drug Administration Web site. Available at:. http://www.fda.gov/cder/pediatric/labelchange.htm. Last accessed November 27, 2007
4. Breslow L.H. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing. Harvard J Legis 40 (2003) 133-193
5. Li J.S., Eisenstein E.L., Grabowski H.G., et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297 (2007) 480-488
6. US General Accounting Office. Testimony before the Committee on Health, Education, Labor, and Pensions, US Senate. Pediatric drug research: substantial increase in studies of drugs for some children but challenges remains. GAO-01-705 T. Available at:. http://www.gao.gov/new.items/d01705t.pdf. Last accessed November 27, 2007
7. IMS Health Inc. IMS Health home page. Available at:. http://www.imshealth.com. Last accessed January 5, 2007
8. Grabowski H.G., Vernon J.M., and Dimasi J.A. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20 Suppl 3 (1994) 11-29
9. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 2 Suppl 4th report (2004) 555-576
10. Hypertension in America: a national reading. Am J Manag Care 11 13 Suppl (2005) S383-S385
11. Hunt S.A., American College of Cardiology, and American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
12. Wilson J.T. An update on the therapeutic orphan. Pediatrics 104 (1999) 585-590
13. Roberts R. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290 (2003) 905-911
14. Ogden C.L., Flegal K.M., Carroll M.D., et al. Prevalence and trends in overweight among U.S. children and adolescents, 1999-2000. JAMA 288 (2002) 1728-1732
15. Meyer A.A., Joharchi M.S., Kundt G., et al. Predicting the risk of early atherosclerotic disease development in children after repair of aortic coarctation. Eur Heart J 26 (2005) 617-622
16. Belay B., Belamarich P., and Racine A.D. Pediatric precursors of adult atherosclerosis. Pediatr Rev 25 (2004) 4-16
17. Daniels S.R. Hypertension-induced cardiac damage in children and adolescents. Blood Press Monit 4 (1999) 165-170
18. Strong J.P. The natural history of atherosclerosis in childhood. Ann N Y Acad Sci 623 (1991) 9-15
19. Lauer R.M., and Clarke W.R. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 84 (1989) 633-641
20. Department of Health and Human Services, and U.S. Food and Drug Administration. Pediatric exclusivity labeling changes as of April 10, 2008. U.S. Food and Drug Administration Web site. Available at:. http://www.fda.gov/cder/pediatric/labelchange.htm Last accessed April 10, 2008
21. Benjamin D.K., Smith P.B., Murphy M.D., et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 296 (2006) 1266-1273